Schering Jumps On Organon Buy; Will Late-Stage M&A Keep Fueling Pharma?
Executive Summary
Pharmaceutical companies unveiling mergers and acquisitions in the first quarter were among those rewarded by Wall Street
You may also be interested in...
Will Schering-Plough’s Vytorin Headache Prove Contagious?
The full impact of Schering-Plough's deepening woes after a scientific panel's negative analysis of the Vytorin ENHANCE trial will not be known for a while, and some analysts predict there could be repercussions beyond the company and its joint venture with Merck, a deal centered on the anti-cholesterol drug, which combines the statin Zocor (simvastatin) withZetia (ezetimibe)
Schering Sees Growth Opportunity For Organon Products In The U.S. – Hassan
Schering-Plough sees significant growth potential for Organon's products that currently are marketed in the U.S., CEO Fred Hassan said March 20
Sanofi Tries To Quash Bristol Rumors; M&A Efforts Center On Biotech, Japan
Sanofi-Aventis' merger and acquisition efforts will focus on biotech firms and Japanese companies, CEO Gerard Le Fur maintained Feb. 13